CellPly

About:

Developing analytical systems to characterize next-generation cancer immunotherapy

Website: https://cellply.com

Twitter/X: cellply

Top Investors: EASME - EU Executive Agency for SMEs, LIFTT, Indaco Venture Partners, Italian Angels for Growth, Horizon 2020

Description:

Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization of cancer immunotherapies, cell therapies and cell-based biotherapeutics. The company aims to support the development of novel cancer immunotherapies by accelerating R&D, automating the quality control and advancing the ability to monitor the clinical response to these treatments. Through the use of proprietary microfluidic technologies with Co-Culture Array technology, highly-automated analytical instruments and AI-powered image and data analytics, Cellply products define the function of the immune system one cell at a time, combining functional data with other multiplex data and providing unprecedented single-cell analytical solutions.